使用立他司特滴眼液有哪些需要注意的地方？

Precautions for use

Advise patients to read the FDA-approved patient labeling. Disposal of disposable containers:

Advise patients not to contact the tip of the disposable container with the eye or any surface to avoid eye damage or contamination of the solution.

For use with contact lenses:

Inform patients that contact lenses should be removed before administration of ritasilast eye drops and can be reinserted 15 minutes after administration.

Give medication

Inform patients that the solution in a single-use container should be used immediately after opening. Can be used for administration to both eyes. Disposable containers (including any remaining contents) should be discarded immediately after administration.

Instruct patients to store the disposable container of Ritalast eye drops in the original aluminum foil bag until ready for use.

Ritalast Eye Drops is contraindicated in patients with known hypersensitivity to Ritalast Eye Drops or any other component of the formulation.

Because systemic exposure to Ritalast Eye Drops in humans is low at the RHOD (recommended human ophthalmic dose), it is unclear whether the results of animal studies apply to the risks of using Ritalast Eye Drops during pregnancy in humans.

The developmental and health benefits of breastfeeding should be considered, as well as the mother's clinical need for Ritalast Eye Drops and any potential adverse effects of Ritalast Eye Drops in the breastfed child.

Safety and efficacy in pediatric patients under 17 years of age have not been established.

No overall differences in safety or effectiveness were observed between older and younger adult patients.

Ritalast eye drops are currently the only prescription drug that treats eye damage caused by dry eye syndrome and relieves its symptoms. Its main component, lifitegrast, is a new type of small molecule integrin inhibitor that reduces the level of inflammation mediated by T lymphocytes by inhibiting the binding of lymphocyte function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM-1).

Ritalast eye drops can not only treat eye damage caused by dry eye disease, but also relieve the uncomfortable symptoms caused by dry eye disease. It has the characteristics of rapid onset, high efficacy and good tolerance. It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Recommended related articles: